Project description
A needle-free shot of adrenaline
Anaphylactic shock is an extreme allergic reaction that needs to be treated immediately with a shot of epinephrine (adrenaline) to reverse the symptoms. Many people at risk of anaphylaxis carry an autoinjector – a combined syringe and concealed needle that injects a single dose of medication. This needle-based drug delivery device may soon be replaced by a needle-free alternative. Crossject’s ZENEO device permits needle-free injection of the drug in emergency situations. Under the EU-funded ZENEO project, the company plans to launch ZENEO® Adrenaline on the market by the end of 2021. It estimates a turnover of EUR 136 million and a profit of EUR 124 million by the fifth year of commercialisation.
Objective
Anaphylactic shock is a serious, life-threatening allergic reaction in which the airways suddenly close; if not properly treated it causes death in 20 minutes. Seventeen million Europeans suffer from food allergies, 3.5 million which are children or young adults. Across Europe, food allergy is the leading cause of anaphylaxis in children aged 0-14 years and there is a huge increase in hospitalizations for allergic reactions in children in the last 10 years. Anaphylaxis sends someone to the emergency room every 3 minutes. The only way to counteract an anaphylactic shock is to inject adrenaline to guarantee enough oxygen to the heart. The adrenaline market is estimated to create revenues of €1.2 billion worldwide, and there is only one big player that produce prefilled syringes.
Crossject already has the know-how to produce pre-filled needle free autoinjectors, our ZENEO® line. We already have 4 ZENEO® products so we are the right company to enter the adrenaline market with a cutting-edge solution.
ZENEO® Adrenaline is an innovative, needle-free, easy-to-use auto-injector suitable for emergency situations, that enables patients and relatives to administer adrenaline. It performs a quick injection (1/10 of a second) avoiding the needle-related discomfort and the risk of contamination, moreover it guarantees intramuscular injection. The end-users of our product are people that are having an anaphylactic shock. People with food allergies are those that will need our device the most as they are more prone to anaphylaxis, however an anaphylactic shock can happen to anyone.
We plan to launch ZENEO® Adrenaline on the market in Q4 2021. We will a turnover of €136M and a profit of €124M by the fifth year of commercialization. We expect to achieve the payback between the second and the third year of commercialization and to generate ROI of 3.36 by the fifth year of commercialization. Moreover, we estimate to create a total of 28 new jobs during these 5 years.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine allergology food allergy
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- natural sciences earth and related environmental sciences environmental sciences pollution
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
21000 DIJON
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.